StoneX Group’s Acurx Pharmaceuticals ACXP Stock Holding History

StoneX Group’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-890	Closed	-$33.8K	–	862
2024 Q3	$33.8K	Buy	+890	New	+$37.7K	0.02%	332

Other funds holding ACXP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACT Advisors Asheville, North Carolina $301M AUM 23.36% 1-Year Est. Return

StoneX Group's ACXP Position: Q4 2024 in Review

StoneX Group sold out of Acurx Pharmaceuticals (ACXP) in Q4 2024, closing a stake of 890 shares — an estimated $33.8K sold.

StoneX Group first reported a position in ACXP in Q3 2024 and held it in 1 quarter. The position peaked at $33.8K in Q3 2024. 26 funds tracked by Wall St. Rank hold ACXP as of Q4 2024.

StoneX Group reported no remaining Acurx Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
StoneX Group sold 890 Acurx Pharmaceuticals shares in Q4 2024, an estimated $33.8K.
StoneX Group first reported a position in Acurx Pharmaceuticals in Q3 2024 and held it in 1 quarter.
StoneX Group's Acurx Pharmaceuticals position peaked at $33.8K in Q3 2024.
26 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q4 2024.

Based on StoneX Group's 13F filing for Q4 2024, filed 12 Feb 2025.